Tag Archives: John Lechleiter

CEOs Sound Out on Health Reform: Stop Swinging from the Fence

At last week’s  4th annual Prix Galien Forum hosted by the Alexandria Center in New York, industry leaders gathered to discuss trends and developments that shape the intersection between science and policy.  The centerpiece of the day was a panel on  US health reform – focused on rollout of the  Affordable Care Act — featuring […]
Posted in Events, leadership, People, R&D, Regulatory | Also tagged , , , , , , , , , , , | Leave a comment

Will "Robust Pipeline" Yield More New Drugs?

Biopharmaceutical companies are touting their huge investment in R&D, which has filled the drug pipeline with more potential first-in-class medicines, including orphan drugs, personalized medicines and new therapies based on novel scientific strategies. A report by the Analysis Group for the Pharmaceutical Research and Manufacturers of America (PhRMA) documents more than 5,000 new medicines in […]
Posted in Biotech, FDA, leadership, R&D, Regulatory | Also tagged , , , , , | Leave a comment

Lower Lilly Earnings the Shape of Things to Come

Eli Lilly announced its first quarter financial results on April 19. But even though the company trumpeted a global revenue growth rate of 9 percent—$5.49 billion, compared to Q1 2009’s $5.05 billion—net income fell 5 percent to $1.25 billion. Part of the blame for that 4 percent difference, the company said, lies with the passage […]
Posted in Strategy | Also tagged , , , , , | Leave a comment
  • Categories

  • Meta